Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

Inclusion Criteria: * Histological diagnosis of adenocarcinoma of the prostate or documented history in medical records of having received treatment for prostate cancer diagnosis * Metastatic disease on chest, abdominal, or pelvic computed tomography (CT) and/or bone scan amenable to biopsy * Hemoglobin (HgB) \> 9.0 gm * Absolute neutrophil count (ANC) \>= 1500 cells/L * Platelets \>= 100,000 u/L * Creatinine =\< 1.5 x upper limit of normal (ULN) * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase (AST)) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase (ALT)) =\< 1.5 x ULN * Castrate serum testosterone level (\< 50 ng/dL -or- \< 1.7 nmol/L) * Progression while on or after androgen deprivation therapy defined as: * Progressive measurable disease: at least a 20% increase in the sum of the longest diameters of measurable lesions over the smallest sum observed or the appearance of one or more new lesions as assessed by imaging during hormone ablation treatment; measurable lesions are nodal or visceral soft-tissue lesions with nodal lesions \>= 20 mm in diameter or visceral/soft-tissue lesions \>= 10 mm in diameter OR * Bone scan progression: appearance of 2 or more new lesions on bone scan during hormone ablation treatment OR * Increasing serum prostate-specific antigen (PSA) level: two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart are required; if the thir…